Purpose : To compare the outcome of trabeculectomy for neovascular glaucoma with or without prior in- travitreal injection of bevacizumab. Cases and Method : We reviewed 26 eyes of 24 cases who received trabeculectomy during the past 39 months. Neovascular glaucoma was due to diabetic retinopathy 17 eyes, retinal vein occlusion 6 eyes, and others 3 eyes. Nine eyes received intravitreal bevacizumab one to 14 days before surgery. Results : Final intraocular pressure (IOP) averaged 11.0± 1.4 mmHg in 9 eyes receiving bevacizumb and 9.0± 1.4 mmHg in the other 17 eyes. When final IOP over 15 mmHg or additional treatment glaucoma was defined as death, rate of survival was 77.7% in 9 eyes receiving bevacizumab and 60.0% in the other 17 eyes 12 months after surgery. There was no significant difference between the two groups. Conclusion : Intravitreal injection of bevacizumab may decrease late complications of trabeculectomy and may induce early IOP control.
|Number of pages||4|
|Journal||Japanese Journal of Clinical Ophthalmology|
|Publication status||Published - Sep 1 2009|
ASJC Scopus subject areas